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Resumo 
 
Já há muito tempo que a humanidade reconhece a importância da interação 
materno-fetal e que as alterações na saúde materna podem ter grande um impacto 
no desenvolvimento do feto. 
Conforme o nosso conhecimento sobre esta interação aumenta, novas patologias 
maternas vão sendo consideradas como maléfica, passando a ser corrigidas, se 
possível, de forma a minimizar os danos no novo ser. 
Nos últimos anos, vários estudos têm provado uma associação clara entre as 
disfunções tiroideias da mãe e alterações no desenvolvimento fetal, principalmente 
no primeiro trimestre da gravidez, quando o feto é totalmente dependência de 
hormona tiroideia materna. 
O maior relevo tem sido dado para as alterações do sistema nervoso central fetal, 
mas a disfunção desta glândula também se associa a subfertilidade, abortamentos 
de repetição, complicações durante a gestação (descolamento da placenta ou pré-
eclampsia tardia) e complicações após o parto, como tiroidite pós-parto. 
Estas provas irrefutáveis, fizeram a comunidade científica ponderar se a intervenção 
actual (rastrear grávidas com risco aumentado de disfunção tiroideia) será 
suficiente, uma vez que estas patologias são frequentes na população e muitas 
vezes assintomáticas. 
Este trabalho tem como objectivo fazer uma compilação de publicações recentes, no 
sentido de compreender se é necessários alargar a população alvo a ser testada e 
se o rastreio universal é viável e vantajoso. 
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1)  Abstract: 
 
Background: As maternal thyroid hormone plays an important role in the fetal 
development, thyroid dysfunction is associated with an increased risk of adverse 
obstetrical outcomes. Therefore, it is of utmost importance that we detect and treat 
the pregnant women with thyroid anomalies in order to prevent an undesired 
outcome. 
Methods: Using article databases such as PubMed and Google academic, books of 
endocrinology and obstetrics and some web sites of medical journals and 
organizations of the last ten years, we collected, synthesized and integrated 
information about the embryology, physiology, histology and imaging of fetal thyroid, 
maternal thyroid disease and their impact on the fetus, the treatment that can be 
offered, the guidelines and the impact of this screening on the course of pregnancy. 
Conclusions:  Universal screening for thyroid dysfunction during pregnancy is a 
desirable end point, but more studies are needed to support its implementation. 
 
Key words: Pregnancy screening, thyroid function, hypothyroidism, hyperthyroidism, 
thyroid antibodies. 
 
Word count: 
- Abstract: 147 
- Body of manuscript: 3652 
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2) Introduction 
 
Since ancient times that we recognize the impact of maternal health in the fetal 
development. As knowledge of maternal-fetal interactions increases, new topics are 
brought up for debate by the scientific community. 
Nowadays, thyroid (dys)function in pregnancy is a new and mediatic topic intensively 
under debate, because there are several and reliable clinical trials that demonstrate 
the negative impact of maternal dysfunction in the development of the fetus. 
For this reason it is mandatory to assess the true impact of thyroid disorders in 
pregnancy and the need to timely screen, diagnose and treat those women at risk.  
This paper compiles the most recent published articles on the impact of thyroid 
(dys)function and the advantages and cost-effectiveness of screening thyroid 
disorders during pregnancy. 
 
3) Methods: 
 
Using article databases such as PubMed and Google academic, books of 
endocrinology and obstetrics and some web sites of medical journals and 
organizations of the last ten years, we collected, synthesized and integrated 
information about the embryology, physiology, histology and imaging of fetal thyroid, 
maternal thyroid disease and their impact on the fetus, the treatment that can be 
offered, the guidelines and the impact of this screening on the course of pregnancy. 
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4) Thyroid gland of the fetus and the mother 
 
4.1) Fetal thyroid embryology  
 
The thyroid gland is the first endocrine glands to develop. It originates from a 
proliferation of endodermal epithelial cells of the pharyngeal floor, between the 
tuberculum impar and the copula, at a point called the foramen cecum, 
approximately on the 24th day after conception. [1] [2] [3] 
The initial thyroid precursor is the thyroid primordium, which proliferates into thyroid 
diverticulum. This structure is initially hollow, but then it becomes a solid mass that 
divides into two lobes connected by an isthmus. [1] 
As the embryo and tongue grow, the gland descends in the neck, passing anterior to 
the hyoid bone and laryngeal cartilages.  At this point, the thyroid is still connected to 
the tongue by the thyroglossal duct, which will obliterate entirely between the 7th and 
10th gestational weeks. As the thyroid gland descends, it develops its adult shape, 
with two lobes connected by an isthmus. By the 7th gestational week, the thyroid 
gland has assumed its definitive form and location immediately anterior to the 
trachea. [1] [2] [3] 
 
4.2) Fetal thyroid physiology 
 
A normal thyroid function during the intra-uterine period is essential for the balanced 
development of the fetus. 
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During the first trimester, fetal thyroid hormone depends on the maternal circulation. 
[4] Evidence has demonstrated that T4 values in celomic fluid vary directly with the 
maternal serum T4 concentrations, proving the important role of transplacental 
passage of maternal thyroid hormone. [4] [5] 
The beginning of fetal thyroid function, at 10th week of gestation, is marked by 
thyroxine (T4) detection. T4 production will gradually rise until reaching the adult 
concentration at approximately 36 weeks. [4] [5] [6] 
Thyroxine-binding globulin (TBG) concentration also increases progressively, 
reflecting the functional maturation of the fetal liver and its increasing capacity to 
synthesize proteins. [4] 
The detection of Triiodothyronine (T3) is also possible early in pregnancy, but the 
concentration levels in the fetal serum are low.  These findings suggest that the 
process that converts T4 in T3 is either immature or not activated, since the major 
source of Free T3 results from the peripheral conversion of T4. [4] 
Thyroid-stimulating hormone (TSH) is measurable around the 12th weeks, and its 
concentration will increase during pregnancy, despite the high serum free T4 
concentrations. This is caused by the immaturity of the negative-feedback system 
until after birth. [4] [5] [6] (Figure 1) 
Since the pituitary-thyroid axis is not yet functioning, the regulation of thyroid 
hormones depends on deiodinase enzymes. For example, in a fetus with 
hypothyroidism, the type II deiodinase increase and type I and III decrease, allowing 
a decline in T3 degradation and a shunting of T4 to the brain. [4] [5] [6] 
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The placenta is also important in thyroid fetal function. This organ is responsible for 
the passage and metabolism of mother’s thyroid hormones. Type II and type III 
deiodinase are present in placental tissue, and their function is to regulate fetal 
exposure to maternal thyroid hormones, converting T4 to T3 (deiodinase II) and T4 
and T3 to reverse T3 and T2 (deiodinase III). For example, the activity of type II 
deiodinase increases when the availability of T4 decreases, maintaining T3 
production in the placenta when maternal serum T4 concentrations are reduced. [5] 
[6] [7] (Figure 2) 
Because of the highly active placental type III deiodinase, the beneficial effects of T3 
are restricted to the placental cells. Some experts even think that the purpose of type 
III deiodinase is to maintain low T3 concentrations in the fetus and to protect 
decidual cells from hypothyroidism. [5] [6] 
Lastly, amniotic fluid is also important in thyroid metabolism. Its pattern reflects the 
maternal and fetal metabolisms. Reverse T3 and T4 (and their sulfatate conjugates) 
account for 95% of thyroid hormones. During the course of gestation RT3 will 
decrease while T4 will increase. [6] 
 
4.3) Fetal thyroid histology 
 
As mentioned before, the initial thyroid precursor is hollow. [1] Then it becomes a 
solid mass composed of follicular cells, parafollicular or C cells and stroma. 
The gland has a follicular structure with a peripheral line of rest follicular cells (with 
round to oval nucleus) attached to a basement membrane cells, followed by a 
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variable number of active thyroid hormone-producing follicular cells packed around 
the central colloid deposit. [8] 
This follicular appearance is similar to the adult thyroid gland, but with more cells, 
smaller follicles and less eosinophilic colloid. [8] As the pregnancy advances, the 
number of follicular cells decreases and their appearance become more cuboidal, 
with eosinophilic and apical cytoplasm. Their secretory activity increases and 
although the hormone synthesis starts early at the 11th week, colloid storage is only 
seen after the start of second trimester. [8] Going into more detail, thyroid histology 
at 12 weeks show small follicular structures with little amount of colloid and round to 
oval cell with few cytoplasm (Figure 3A); on the 17th week there is an increase of the 
eosinophilic colloid inside the follicles and of the cells cytoplasm (Figure 3B). On the 
36th week of gestation the gland presents histology similar to the adult thyroid with 
large eosinophilic follicles, surrounded by cuboidal cells with an apical cytoplasm 
(Figure 3C). 
C cells are distributed between follicular cells and their function is to secrete 
calcitonin, a hormone that regulates calcium. [9] Their identification with hematoxylin-
eosin is very difficult in the fetal thyroid. Therefore, immunohistochemic and 
grimelius silver methods are used to identify them. [8] 
The stoma is the fibrous tissue and blood vessels that surrounds the follicular 
structures and its function is to support and nurture the thyroid cells. [8] 
Fetal thyroid has also a fibrous capsule that limits the gland as the adult thyroid, but 
unlike the latter, fetal thyroid does not have lipofusion pigment. This is an important 
characteristic since the presence of pigments represents a thyroid anomaly. [8] 
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4.4) Maternal thyroid disease and it impact on the fetus 
 
Pregnancy represents a challenge for the thyroid gland. During this period major 
changes like the enlargement of the thyroid, the increase of thyroid blood flow, 
hormones and binding proteins and alterations in iodine handling are noticed. [10]  
These hormones contribute to the correct development of the fetus and any maternal 
thyroid dysfunction can result in an adverse outcome.  
The presence of thyroid antibodies occurs in 10% of women at 14 weeks of gestation 
and it is associated with a poor pregnancy prognosis. Their presence increases the 
risk of developing hypothyroidism. A pregnant woman with normal thyroid function 
but positive antibodies must be followed during pregnancy. [11] 
The presence of antibodies is a risk factor of complications, independent of hypo or 
hyperthyroidism, like miscarriage, premature delivery, placenta abruption and 
subfertility. [11] [12] [13] [14] Their presence might even serve as a marker for other 
autoimmune conditions that can also increase the risk of fetal death. [15] 
The antibodies are also associated with an increase in maternal complications like 
post-partum thyroiditis. [13] 
Hypothyroidism is another maternal disorder that can affect the fetus. It occurs in 
2.5% of women and can be caused by autoimmune disease or suboptimal iodine 
intake. [11] [16] 
Early detection of hypothyroidism is crucial because the increase in TSH has been 
associated with impaired neuropsychological development of children [17] [18] and 
several other adverse outcomes, including spontaneous early preterm delivery [19], 
 Pág. 10 
 
late-preeclampsia, miscarriage [20], fetal death and recurrent pregnancy loss [21] 
[22] [23]. 
The biggest problem is that this dysfunction is particularly difficult to diagnose 
because it can be subclinical and even when the pregnant woman has symptoms, 
the clinical manifestations are quite similar to normal pregnancy complaints 
(drowsiness, fatigue, extreme weight gain, constipation, hair loss, dry skin, general 
malaise). 
Hyperthyroidism is found in 0.2% of all pregnancies and is usually due to Graves’ 
disease (which improves in the pregnancy). [11] [16] This dysfunction has been 
related to preterm delivery, miscarriage and placenta abruption. It also increases 
maternal morbidity due to the risk of congestive heart failure, thyroid storm and 
preeclampsia in women with uncontrolled hyperthyroidism. [11] [16].  
Unlike hypothyroidism, sub-clinical or mild hyperthyroidism does not increase fetal or 
maternal morbidity. It is more readily diagnosed by a careful history, physical exam 
and laboratory testing. I 123 is very useful for thyroid scanning but it is contraindicated 
in the pregnancy due to its radioactivity that can be concentrated in fetal thyroid. [24]   
 
5) Thyroid disease 
 
5.1) Thyroid  function screening 
 
Screening comprises the systematic application of a test or inquiry for a disease, to 
the general population, to detect those individuals at high risk of being affected by 
 Pág. 11 
 
the disease. Since thyroid dysfunction has a negative impact on the mother and 
fetus, universal screening of this hormonal dysfunction has been under debate. 
Currently, the American College of Obstetricians and Gynecologists (ACOG) 
recommends thyroid testing only in high-risk pregnant women who are symptomatic 
or have a personal history of thyroid disorders, type 1 diabetes or other autoimmune 
disorders. [25] As ACOG, the American Thyroid Association and the American 
Association of Clinical Endocrinologists also recommend aggressive case finding 
instead of universal screening. [26] 
Not only who should be tested should be under debate, but also methods and cut-
offs of the screening because there are no reliable population studies with reference 
intervals. 
Guidelines recommend serum TSH as the initial test [25] because of its high 
sensitivity and specificity in the diagnosis of thyroid dysfunction [11] [27]. However, 
due to the thyroid-pituitary instability during pregnancy it is clearly insufficient alone. 
[28] 
As total and free thyroid hormones measurement can be influenced by the elevation 
of TGB and very likely can lead to a wrong diagnosis, they cannot be used alone. 
[29] But some studies report that the combination of TSH and FT4 (free thyroxine) is 
the most sensitive method of screening [28] and this association seems particularly 
useful in low iodine countries where the prevalence of isolated hypothyroxinemia 
(low FT4 and normal TSH) is higher. [18] [30] 
Thyroid antibodies like Thyroid peroxidase antibody (TPO-ab) can also be used in 
the screening to detect and treat early thyroid autoimmune disease. Their 
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measurement allows us to predict the risk of thyroid dysfunction and obstetric 
complications during the pregnancy. [28] Some authors advocate that this test must 
be associated with TSH determination in high-risk women for autoimmune diseases 
[30]. TSH plus TPO can also be very beneficial if performed before conception. [31] 
In order to make all these measurements meaningful there is still an unsolved 
problem: the heterogeneity of both methods and population. Population based 
reference ranges need to be established, as well as remove several confounding 
factors such population composition, iodine intake, laboratory methods and the 
individual and genetic set point. [28] 
 
5.2) Imaging of  fetal thyroid 
 
The prenatal scan is used to detect fetal goiter, enlargement and/or different coloring 
patterns of fetal thyroid gland, in situations of thyroid dysfunction. 
Fetal goiter can be associated with fetal hyperthyroidism in cases in which maternal 
thyroid-stimulating antibodies cross the placenta stimulating the fetal thyroid (Figure 
4), [32] or more rarely, with fetal hypothyroidism. The latter is usually caused by a 
primary metabolic thyroid disorder, transplacental passage of thyroid-inhibiting 
antibodies or the excessive treatment of hyperthyroidism. [32]  
By adding the Doppler technique to the ultrasound examination we are able to 
differentiate fetal hyper from hypo-function of thyroid gland, because hyperthyroidism 
causes an increase in central blood flow, while hypothyroidism presents more 
typically with a more peripheral vascularization. [33] (Figure 5) 
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Fetal thyroid control in the womb is very important when we are treating a maternal 
thyroid disease like Graves disease. This allows the stricter control of mother 
dysfunction avoiding fetal hypothyroidism. [33] [34] 
MRI (magnetic resonance imaging) is another way of studying the fetal thyroid, but is 
a more expensive method (Figure 6). 
The presence of fetal thyroid changes as observed by imaging requires the 
evaluation of both mother and fetus thyroid status. [32] 
  
6) Treatment 
 
Once thyroid dysfunction is proved to be harmful, its prevention and treatment are 
very important. 
As a start, all pregnant women should be prescribed additional iodine intake 
(150µg/day) to avoid iodine deficiency. [35] Another important measure is to treat 
every woman of childbearing age with known thyroid dysfunction, because it is well 
recognized that if they get pregnant while euthyroid the risk of fetal adverse outcome 
is equal to the general population [35]. 
The treatment of hypothyroidism is based on replacing the hormone with 
levothyroxine. The dose needed depends on several factors and has to be adjusted 
periodically, by monitoring thyroid function every 4/6 weeks, until 16/20 weeks and 
then less frequently. This monitoring scheme is based on the fact that levothyroxine 
dosage needs to be increased until 16 to 20 weeks and then they reach a plateau 
[35] [36].  
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To those women who are already taking levothyroxine it should be explained that 
they have to increase their standard dose each week by 29%. [36]  
Apart from its use in hypothyroidism, levothyroxine can also be useful in reducing the 
risk of miscarriage and premature birth in euthyroid women with autoimmune thyroid 
disease. [37] 
 Hyperthyroidism has several forms of treatment but not all can be used in pregnant 
woman. The pharmacologic treatment is one of the most common choices and it is 
based on the use of antithyroid drugs like methimazole (MMI) and propylthiouracil 
(PTU). [38]  
Because MMI is associated with embryologic defects like aplasia cutis, atresias 
(choanal and esophageal) and PTU with liver disease, [34] [35] [38] some authors 
advocate that PTU should be used in the first trimester and, once embryogenesis 
has been completed, switched to MMI. [35] Both drugs can cause agranulocytosis, 
which is the most serious complication and requires immediate cessation of therapy. 
[35] [38] The dose used must be the lowest possible to repair the mother’s normal 
function, because these drugs can cross the placenta causing fetal hypothyroidism. 
[35]  
β-Blockers, like propanolol, can also be use temporarily to reduce the symptoms 
associated with overachieving function (tachycardia, anxiety, weight loss), but 
because these drugs can be harmful to the uterine blood flow and can cross the 
placenta affecting the fetus development, they must be discontinued as soon as the 
symptoms improve. [35] [39]. The dose of β-Blockers must be adjusted to keep the 
maternal heart rate between 70 to 90 beats per minute. [38] 
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Finally, thyroidectomy can also be considered in pregnant woman in who medical 
control cannot be achieved. [35] Surgery must be delayed until after the first 
trimester. [38]  
 
7) Discussion 
 
Thyroid dysfunction, a common anomaly in reproductive age women [16], increase 
the risk of obstetric complications such as impaired neuropsychological 
development, early preterm delivery, preeclampsia, fetal death and recurrent 
pregnancy loss. [40] [12] [20] [17] [41] [19] [42] [43] 
It is therefore important that we answer three questions: WHO should we test? 
WHEN would it be soon enough? And HOW can we detect this dysfunction? 
 
WHO?   
Vaida et al. conclude in one of their studies that testing only high risk women would 
miss one third of pregnant women affected by thyroid anomalies. [18] A posterior 
study obtained an even higher percentage, claiming that 55% pregnant women 
would be missed if we use the current guidelines. [13]  
It seems no longer acceptable to leave one third of women under diagnosed, when 
the negative impact can be so great and the diagnosis and treatment so easily 
accessible. [44]  
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Another important fact about case finding instead of universal screening is that it 
cannot ensure equal care to all pregnant woman. Some studies prove that women 
were more likely to be detected if they were evaluated by an obstetric urban 
practitioner than by a family rural one. [45] This idea was reinforced by the Chang et 
al. study that focused on women with socioeconomically disadvantaged 
backgrounds. They obtained even more dramatic results than Vaida et al., who had 
80% undiagnosed pregnant women with increased TSH. [46] 
On the other hand, Negro et al. conclude that universal screening does not decrease 
the negative outcomes compared to case finding because adverse outcomes are 
less likely to occur in low risk women. 
Cost-effectiveness studies have demonstrated that screening is economically 
beneficial [47] or even cost saving compared to no screening. [48] [26] But the true 
cost-effectiveness of the universal screening can only be proved by a randomized 
controlled trial. [26] 
Some experts say that universal screening is not yet proven as the best solution [49] 
and, based on this absence of evidence, the American Thyroid Association, the 
American Association of Clinical Endocrinologists, the Endocrine Society and the 
American and College of Obstetrics and Gynecology recommend aggressive case 
finding instead of universal screening. [50] [24] 
Hossein et al. reinforces the idea that their guidelines are based on a “lack of 
evidence for benefit rather than on evidence for a lack of benefit” and for the author 
this is an inadequate decision. [51] 
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WHEN?  
Most of the trials tend to test the thyroid function on the first trimester (first antenatal 
visit) [18] [13] [48] but is it soon enough?  
The answer is maybe not because the fetus is most dependent on maternal thyroid 
in the first half of pregnancy (mainly on the first 13 weeks) [18] and nervous system 
development is already achieved by the first antenatal visit, so diagnosis and 
treatment of the thyroid dysfunction at this time may not prevent the total damage of 
this organ [11] 
For this reason, it is generally agreed that screening should be done as early as 
possible, [52] even at the pre-conception visit so women can correct their thyroid 
dysfunction before getting pregnant. [31] 
Another important point is that first trimester or pre-conception screening alone only 
allows the detection of disorders that occurred prior to pregnancy, missing those that 
appear later. [52] It is now relevant to establish if late dysfunction that appears in a 
less dependent fetus has also a negative impact and if it is worthwhile to test them.  
 
HOW?  
Serum TSH determination is the test approved by the guidelines. It is regarded as 
the most sensitive and specific method to screen pregnant and no pregnant women, 
[29] but it still has not appropriate reference values to the pregnant population. [13]  
Serum Free T4 is also useful to establish thyroid function, particularly in countries 
with low iodine consumption because they have a greater prevalence of isolated 
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hypothyroxinemia. [18] The problem of this test is that the increase of TBG will 
hinder the correct interpretation of its value. Some authors suggest using Total T4 
(TT4) with 100nmol cut-off instead. [29] 
TPO antibodies can also give important information about pregnancy outcome. 
Besides increasing the risk of hypothyroidism, TPO-ab are also associated with 
adverse outcome by themselves. [13] 
Expert opinions on which further tests to use are still mixed. Some think that serum 
TSH alone is enough to screen [30] but others disagree [28]. On low iodine 
countries, the TSH plus FT4 association seems very important, once the TSH 
determination alone would miss 40% of the dysfunction. This association seems to 
have the greater number of followers, even in countries without iodine deficits. [30] 
[29] 
Some defend that TSH-TPO association would be ideal, particularly in the pre-
conception period. [31] 
In the midst of disagreement, all seem to agree that we need randomized controlled 
trials that prove the impact of treating these maternal dysfunctions. [18] But this trial 
can take a long time to be implemented because we can only evaluate correctly the 
negative impact on neuropsychological development and QI during childhood. 
Until then, aggressive case finding is going to prevail. So it is very relevant alert the 
pregnant caregivers to the importance of thyroid dysfunction so they can diagnose 
and treat more often this kind of dysfunction. 
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8) Guidelines 
The American College of Obstetricians and Gynecologists guidelines [24]: Screening 
of all pregnant women with a personal history, physical examination, or symptoms of 
a thyroid disorder. 
The Endocrine Society Clinical Practice Guideline [50]: case finding should be 
recommended among the following groups of women at high risk for thyroid disease 
by measuring TSH:  
a) Women with a history of hyperthyroid or hypothyroid disease, premature delivery 
or thyroid lobectomy. 
b) Women with a family history of thyroid disease. 
c) Women with a goiter. 
d) Women with thyroid antibodies (when known). 
e) Women with symptoms or clinical signs suggestive of thyroid underfunction or 
overfunction, including anemia, elevated cholesterol, and hyponatremia.  
f)  Women with type I diabetes. 
g)  Women with other autoimmune disorders. 
h)  Women with infertility who should have screening with TSH as part of their 
infertility work-out. 
i) Women with previous therapeutic head or neck irradiation. 
j) Women with a history of miscarriage or preterm delivery. USPSTF 
recommendation level is B; evidence is fair (GRADE 1)”  
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9) Conclusions: 
 
A universal screening of thyroid dysfunction in the pregnancy is a desirable end 
point, but more studies need to be done to support its implementation and clinical 
justification. 
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12) Legends to the figures 
 
Figure 1 - Relative changes in maternal and fetal thyroid hormones during 
pregnancy. (Adapted from N Gerard et al, 1994) 
Figure 2 - Interrelations of maternal, placental, and fetal pathways in thyroid function 
during pregnancy. (Adapted from N. Gerard et al, 1994) 
Figure 3 - Thyroid histology at 12 weeks (3A) shows small follicular structures with 
little amount of colloid and follicular cells with few cytoplasm; on the 17 th 
week (3B) there is an increase of the eosinophilic colloid inside the 
follicles and of the cells cytoplasm. On the 36th week of gestation (3C) 
the gland presents histology similar to the adult thyroid with large 
eosinophilic follicles, surrounded by cuboidal cells with an apical 
cytoplasm (courtesy of O. Brandão). 
Figure 4 – Ultrasound bidimensional image from a fetal goiter presenting as a 
voluminous mass in the fetal neck.  (Courtesy of A. Matias) 
Figure 5 – Fetal hypothyroidism is evidenced by Doppler ultrasound as presenting 
with a more peripheral vascularization pattern in the fetal thyroid. 
(Courtesy of A. Matias) 
Figure 6 - MRI of the fetus thyroid showing fetal goiter. (Courtesy of A. Matias) 
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Anexos 
 
Autorização de reprodução de imagens: 
 
Imagens 1 e 2: confirmação por email: gerard.burrow@yale.edu   
“Assunto - Permission to reproduce copyrighted materials: 
Joana, 
You have my permission to use Figures 1&3 from my article "Fetal and 
Maternal Function. 
Good Luck with your thesis and in Medicine. 
Gerard N. Burrow,M.D.” 
 
Imagens 3A, 3B e 3C: confirmação por email: o.brandao@portugalmail.pt 
“Assunto - : 
É com muito gosto que cedo as imagens acima referidas com o objectivo 
de serem utilizadas na sua tese de mestrado. 
Esperando, também, ter sido útil, desejo que tudo corra bem. 
Até sempre e com os melhores cumprimentos, 
Otilia Brandao” 
 
Imagens 4, 5 e 6: confirmação por email: almatias@mail.telepac.pt 
“Assunto - Pedido de permissão para utilizar material já publicado: 
Estimada Joana Félix, 
“As imagens contidas na sua monografia correspondentes ao caso clínico 
"Tiroxina intra-amniótica no tratamento do bócio fetal hipotiróideu" podem 
ser usadas na tese de mestrado e qualquer publicação que daí decorra. 
Cumprimentos 
Alexandra Matias”   
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Methods: 
Using article databases such as PubMed and Google academic, books of 
endocrinology and obstetrics and some web sites of medical journals and 
organization of the last ten years, we collected, synthesized and integrated 
information about the embryology, physiology, histology and imaging of fetal thyroid, 
maternal thyroid disease and their impact on the fetus, the treatment that can be 
offered, the guidelines and the impact of this screening on the course of pregnancy. 
 
 Fetal Thyroid embryology: 
The Developing Human: clinically oriented embryology (8th ed.) – (1) 
Langman's Medical Embryology – (2) 
Medscape: key Word: “thyroid embryology” – (3) 
 
 Fetal thyroid physiology: 
PubMed: key word “fetal thyroid function” – (4) PMID: 1422233, (5) PMID: 19901830, 
(6) PMID: 8090169 
Google academic:  key word “fetal thyroid function” – (7) 
 
 Fetal thyroid histology 
Google books: KEY WORD: “Histology of thyroid gland” – (8) AND (9) 
 
 Maternal thyroid disease and it impact on the fetus: 
Pubmed: key words “physiology of thyroid function in pregnancy”, “thyroid disease in 
pregnancy”, “Maternal Thyroid Function at 11 to 13 Weeks” – (10) PMID: 
382166, (11) PMID: 15858112, (12) PMID:20718684, (14) PMID:21857181, 
(15) – PMID: 11126160, (16) – 12487768, (17) PMID: 10451459, (18) PMID: 
17032713, (19) PMID: 18984665, (20) PMID: 20865794 and (22) PMID: 
18923214  
Google academic: “maternal thyroid and pregnancy complications”, “epidemiology of 
thyroid disease in pregnancy”, “maternal thyroid disease”, “TSH pregnancy 
miscarriage, pregnancy loss, fetal death” – (13), (21) 
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 Thyroid function screening: 
Pubmed:  key words “universal screening thyroid in pregnancy”, “thyroid disorders to 
obstetrician”. – (23) PMID: 199273570, (26) PMID: 19114278, (27) PMID: 
20531379, (28) PMID: 21512584 and (29) PMID:15687823 
American college of obstetricians and gynecologist: thyroid guidelines - (25) 
American thyroid association (www.thyroid.org) – key word “thyroid disease and 
pregnancy). – (24) 
 
 Images of fetal thyroid: 
PubMed: key word “fetal thyroid ultrasound” and “ultrasound in obstetrics” – (30) 
PMID: 21411022, (31) PMID: 20375219 
Google academic: key word “fetal thyroid ultrasound”, “ultrasound in obstetrics” – 
(32) 
Thyroid disease manager – chapter 6 ultrasonography of the thyroid – (33) 
 
 Treatment 
PubMed: Key words: “levothyroxine during pregnancy”, “hyperthyroidism in 
pregnancy treatment” and “intervention for hypothyroidism in pregnancy” – 
(34) PMID:16118343, (36) PMID: 15254282, (37) PMID: 16621910 
Book: Management of Common Problems in Obstetrics and Gynecology fifth edition 
(35) Chapter 23 - Thyroid Disease in Pregnancy: Hyperthyroidism and chapter 
24 - Thyroid Disease in Pregnancy: Hypothyroidism 
 
 Discussion: 
PubMed: “maternal thyroid function at 11-13 weeks”, “hyperthyroidism and 
hypothyroidism in pregnancy”, “thyroid and pregnancy” and “cost-
effectiveness screening pregnant thyroid function” -  (38) PMID: 10447008, 
(40) PMID: 21252742, (41) PMID: 11397821, (42) PMID: 21687610, (43) 
PMID: 15142372, (44) PMID: 17209222, (45) PMID: 16458648, (46) PMID: 
21715539, (47) PMID: 18762789, (48) PMID: 18505905 and (49) PMID: 
14722150 
The Journal of clinical Endocrinology and Metabolism: “thyroid and pregnancy”- (51) 
Google academic: – “thyroid dysfunction during pregnancy” and “screening thyroid 
status in pregnancy” – (52) 
Book: Clinical gynecologic endocrinology and infertility 8th edition – (39) 
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